This review outlines the molecular targets and clinical trial results of new parenteral and oral anticoagulants for the prevention and treatment of thrombosis.
Offers overview of emerging anticoagulants; leaves open optimal selection pending comparative trials.
The development of new anticoagulants is expanding the list of drugs that can be used to prevent and treat venous and arterial thrombosis. New parenteral anticoagulants have been developed to overcome the limitations of heparin and low-molecular-weight heparin, whereas novel orally active anticoagulants have been designed to provide more streamlined therapy than vitamin K antagonists. This review identifies the molecular targets of new anticoagulants, describes the results of clinical trials, and provides clinical perspective on the opportunities for new anticoagulants.
No takes yet. Share an insight, caveat, or question.
Linkins et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: